Navigation Links
PTC Therapeutics Reports Third Quarter 2013 Financial and Corporate Results
Date:11/14/2013

on revenue includes deferred revenue from payments received in previous periods as well as payments received and recognized during the respective periods. 
  • Total operating expenses were $20.6 million for the third quarter of 2013, including $2.6 million in stock based compensation expense, compared to $14.3 million for the same period in 2012, including $0.5 million in stock based compensation expense.  The increase was primarily due to higher research and development expenses related to the initiation of the Phase 3 clinical trial of ataluren for the treatment of nmDMD, as well as higher general and administrative expenses related to public company expenses and pre-commercial activities. 
  • Net loss for the third quarter of 2013 was $4.4 million compared to a net loss of $7.3 million for the same period in 2012.
  • Shares issued and outstanding as of September 30, 2013 were 24.9 million, which includes 1.1 million of unvested restricted stock.
  • Today's Conference Call and Webcast Reminder
    The PTC management team will host a conference call to discuss the company's financial results and recent and upcoming developments today, Thursday, November 14, 2013, at 8:00 a.m. ET. The call can be accessed by dialing 877-303-9216 (domestic) or 973-935-8152 (international) five minutes prior to the start of the call and providing the passcode 24942756.

    The live, listen-only webcast of the conference call can also be accessed by visiting the "Investors Relations" section of the company's website at ir.ptcbio.com. A replay of the webcast will be archived on the PTC website for 30 days following the call.

    About PTC Therapeutics, Inc.
    PTC Therapeutics is biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes re
    '/>"/>

    SOURCE PTC Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Aratana Therapeutics Reports Third Quarter 2013 Financial Results
    2. Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for Possible Violations of Federal Securities Laws
    3. Argos Therapeutics to Present at the Elsevier Therapeutic Area Partnerships Meeting
    4. Mirati Therapeutics Reports Third Quarter 2013 Financial Results
    5. Sorrento Therapeutics Adopts Stockholder Rights Plan
    6. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
    7. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
    8. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
    9. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
    10. Echo Therapeutics Announces Third Quarter 2013 Financial Results
    11. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
    (Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
    (Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
    Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
    ... WA – June 25 – MediQuest Therapeutics,Inc., ... for inflammatory and infectious diseases, today announced,the ... of Vascana,– a topical formulation designed to ... primary end point and demonstrated statistical,significance, with ...
    ... Company updates progress and upcoming,milestones on its ... /PRNewswire-FirstCall/ - SemBioSys,Genetics Inc. , a biotechnology ... metabolic and cardiovascular disease,today announced positive preclinical ... insulin. The Company,presented its findings at the ...
    Cached Medicine Technology:MediQuest Concludes Confirmatory Phase III Study of Raynaud’s,Therapy 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 3SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 4
    (Date:4/23/2014)... Inverse Effects of Midlife Occupational and Leisure Time Physical ... occupational physical activity in midlife increases the risk of ... decreases the risk. This is found in a study ... years. The study was conducted at the Gerontology Research ... Health. , Heavy physical labor is often repetitive, wears ...
    (Date:4/23/2014)... depletion of self-control, according to research published in ... Psychological Science. , Self-control can be difficult sticking ... a boring textbook are hard things to do. Considerable ... self-control for a long period seems to "deplete" our ... "It is as if self-control is a limited resource ...
    (Date:4/23/2014)... of Alzheimer,s disease has been a rapidly evolving ... the latest crook in the research road, scientists ... between proteins associated with the disease. The report, ... Neuroscience , could have important implications for developing ... and colleagues explain that for years, research has ...
    (Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
    (Date:4/22/2014)... researchers have characterized a set of clock genes that ... types of species, from flies to humans. Over 15 ... there are more. A team from the Perelman School ... big-data approaches could find them. , To accelerate ... professor of Pharmacology and first author Ron Anafi, MD, ...
    Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
    ... networks in fruit flies has led researchers to a sensitive ... most common type of kidney cancer. In the journal ... at the University of Chicago shows that the biomarker known ... renal cell carcinomas but not by normal kidney tissue. , ...
    ... new 30" in groundbreaking new calendarHAGATNA, Guam, Jan. 27 ... natural calendar to promote her "Look Good Naked" theme ... is beautifully captured au natural and semi-nude in high-quality ... in her beautiful cottage home. "I wanted to show ...
    ... HCA Healthcare announces the following Webcast:, What: ... 10:00 EST, Where: http://www.videonewswire.com/event.asp?id=55052 , How: ... web at the, ... +1-615 344 ...
    ... Jan. 27 /PRNewswire-FirstCall/ - QLT Inc. ("QLT") (NASDAQ: ... modified "Dutch Auction" tender offer (the "Offer"), which expired at ... on the preliminary report of the depository for the Offer, ... shares (the "Shares") at a price of US$2.50 per Share, ...
    ... -- The University of Texas at San Antonio (UTSA) ... College of Engineering has been awarded a $199,884, 24-month ... energy combustion. , "This is one of the first ... combustion, gasification and energy efficiency," said Efstathios Michaelides, mechanical ...
    ... adds affordable, professionally refurbished Hill-Rom hospital beds to its ... ... -- DRE Medical Equipment — named by Business First of Louisville ... refurbished Hill-Rom hospital beds . DRE’s extensive lineup of economically-priced ...
    Cached Medicine News:Health News:Roadkill study could speed detection of kidney cancer 2Health News:QLT announces preliminary results of tender offer 2Health News:QLT announces preliminary results of tender offer 3Health News:UTSA receives federal funding for fossil fuel research 2Health News:DRE Medical Equipment Now Sells Reconditioned Hill-Rom Hospital Beds 2Health News:DRE Medical Equipment Now Sells Reconditioned Hill-Rom Hospital Beds 3
    For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
    For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
    For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
    For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
    Medicine Products: